CDC Issues Guidance on COVID-19 Rebound After Paxlovid Treatment
Recent case reports suggest that some patients treated with Paxlovid may have a recurrence of COVID-19 symptoms 2 to 8 days after completing the 5-day course.
Recent case reports suggest that some patients treated with Paxlovid may have a recurrence of COVID-19 symptoms 2 to 8 days after completing the 5-day course.
The Agency is currently seeking public comment on this potential modification to the existing Opioid Analgesic Risk Evaluation and Mitigation Strategy.
The Emergency Use Authorization was based on safety and immunogenicity data provided to the Agency.
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
Molnupiravir is an orally administered form of a ribonucleoside analogue that inhibits the replication of SARS-CoV-2.
Findings from an ongoing randomized, placebo-controlled, observer-blind phase 3 trial showed Spikevax was 93.2% effective at preventing COVID-19.
Concise drug information for molnupiravir and Paxlovid; the FDA granted Emergency Use to both oral antiviral therapies.
Several pharmacotherapies have been shown to reduce pain in patients with painful diabetic neuropathy.
Individuals in this age group should only receive this vaccine as their booster.
The CDC is recommending that health care providers take a travel history for all suspected and confirmed cases of COVID-19.